Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Discover OncologyOpen Access

Systematic network pharmacology and experimental validation reveal anti-glioma mechanisms of ganoderma lucidum via multi-target regulation

View Full Paper
Ask AI
Bookmark
Share

Authors

XMXue MeiJZJufen ZhangLCLu Chen

Discussion

Loading...

Member takes

Overview

Systematic network pharmacology identifies beta-sitosterol’s role in glioma therapy, suggesting TCM potential.

Key Points

  • Beta-sitosterol significantly inhibits glioma cell viability and migration, showing promise as a therapeutic agent.
  • Analysis identified 16 active compounds and 86 glioma-related targets, emphasizing the multi-target nature of Ganoderma.
  • Network pharmacology methods revealed significant pathways involved in glioma, including GPCR signaling and steroid metabolism.
  • Expression analysis confirmed the clinical relevance of hub genes like CASP3 and PTGS2, linking them to glioma outcomes.

Cite This Study

Mei et al. (2025) studied this question.

synapsesocial.com/papers/68c1b18b54b1d3bfb60e895fhttps://doi.org/10.1007/s12672-025-03280-x
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Zika Virus: A Neurotropic Warrior against High-Grade Gliomas—Unveiling Its Potential for Oncolytic Virotherapy2024 · 8 citations
  2. 2Glioma cancer stem cells modulating the local tumor immune environment2022 · 8 citations
  3. 3Hybrid Membrane Biomimetic Photothermal Nanorobots for Enhanced Chemodynamic-Chemotherapy-Immunotherapy2025 · 19 citations
  4. 4Neural Stem Cells as Potential Glioblastoma Cells of Origin2023 · 57 citations
  5. 5Advances in Preclinical/Clinical Glioblastoma Treatment: Can Nanoparticles Be of Help?2022 · 31 citations